Steps to complete the survey:
1. Click on Sign In button and login/register from your account.
2. Click on Participate button, and you will be directed to the survey page.
3. Fill in the survey and submit.
Diabetes mellitus is a prevailing disease as well as associated with micro and macrovascular complications that further add to the mortality in these patients. Although many treatment options and regimens are available, the focus shall be on reducing cardiovascular-associated risk factors along with glycemic control. Thus it becomes very imperative to have an approach that is an optimal choice having glucose lowering as well as preventing cardiovascular events in early-stage type 2 diabetes. In view of this, a survey is conducted to compare the efficacy of the FDC of dapagliflozin and sitagliptin in treating type 2 diabetes mellitus and its impact on HbA1c levels and body weight, safety profile, and CV outcomes. This survey aims to highlight the potential benefits, rationale, and efficacy as well as safety of this drug combination across different groups of patients.
Course objectives:
1. To evaluate various patient profiles for Sitagliptin + dapagliflozin
2. To understand the tolerability, safety, and efficacy of sitagliptin + Dapagliflozin
3. To establish the role and rationale of this FDC use, especially in Diabetic patients with CV disease.
4. To derive the best treatment regimen in T2DM management along with a reduction in overall CV mortality.